Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BetterLife Pharma’s (CSE:BETR) launch of its branded products is still on target, despite disruptions to the global supply chains 
  • The company will launch its white-labelled and patent-protected products in 2020’s second quarter
  • BetterLife is accelerating the launch of CBD supplements product line in the third quarter
  • The company has also announced an amicable resolution to its disputes with former executives, Patrick J Rolfes and Ross Franklin
  • BetterLife Pharma’s (BETR) share price remains unchanged, and is currently trading for 7.5 cents per share

BetterLife Pharma’s (CSE:BETR) launch of its branded products is still on target, despite COVID-related disruptions to global supply chains.

The company intends to launch its white-labelled and patent-protected products in a direct-to-consumer model in 2020’s second quarter.

The first range of products to launch under the brand available in the US will include topicals, tinctures and gummies. 

In addition, BetterLife is accelerating the launch of a CBD supplements product line in the third quarter. The line will include CBD multi-benefit supplements and immunity-boosting products. 

The company could be accelerating the launch in order to capitalise on increased demand for CBD products, caused by COVID-19. Many cannabis companies have reported significant increases in sales since fears started setting in about the pandemic. 

BetterLife’s Interim CEO, Ahmad Doroudian, commented on how the company is getting on with the job. 

“During the first quarter, BetterLife’s operations and scientific team successfully transferred its formulations to commercial manufacturing facilities in the US. Mr Joseph Mimran and his consulting firm developed the branding and packaging for our branded products.

I want to thank both teams, who worked tirelessly in a very challenging environment to ensure the successful launch of our products in the coming weeks,” he said.

BetterLife has indicated that it will continue to aggressively pursue opportunities for mergers and acquisitions in the future. 

In other news, the company has announced an amicable resolution to all of its disputes with former executives, Patrick J Rolfes and Ross Franklin. 

BetterLife Pharma’s (BETR) share price remains unchanged, and is trading for 7.5 cents per share as of 2:05pm EST.

More From The Market Herald
Featured Video Play Icon

" OpSens (TSX:OPS) announces first SavvyWire procedure in the U.S.

OpSens (OPS) is announcing the first SavvyWire procedure in the U.S.

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.
Featured Video Play Icon

" Rapid Dose Therapeutics (CSE:DOSE) to supply leading gas and convenience store retailer

Rapid Dose (DOSE) has signed a supplier agreement with a leading gas and convenience store retailer.

" NervGen Pharma (TSXV:NGEN) announces leadership changes

NervGen Pharma Corp. (NGEN) has announced several leadership changes.